Showing 4091-4100 of 5957 results for "".
- IntRIS Hosts ARCR Macular 2024 Meeting and Presents Interview With FDA’s Dr. Wiley Chambershttps://modernod.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/The International Retinal Imaging Society (IntRIS) hosted the Atlantic Coast Retina Club (ACRC) Macula 2024, led by K. Bailey Freund, MD. According IntRIS, the ACRC meeting format includes rapid-fire single-case presentations, engaging discussions, and conferences covering diverse retin
- Harrow Launches Dry Eye Drug Vevye in the United Stateshttps://modernod.com/news/harrow-introduces-vevye-in-united-states-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2482053/Harrow announced that Vevye (cyclosporine ophthalmic solution) 0.1% is now available in the United States. It is indicated for treating the signs and symptoms of dry eye disease (DED). Vevye is the company’s nonpreserved, twice-daily dosed prescription drug based on a water free s
- Nidek Launches Mirante Scanning Laser Ophthalmoscope in the United Stateshttps://modernod.com/news/nidek-launches-mirante-scanning-laser-ophthalmoscope-in-the-united-states/2482052/Nidek announced the commercial launch of the Mirante Scanning Laser Ophthalmoscope (SLO) in the United States. The Mirante is a multimodal fundus-imaging platform that combines high-definition SLO and optical coherence tomography (OCT) with ultra-wide field imaging. The multimodal platf
- EyePoint Begins Phase 2 VERONA Clinical Trial of EYP-1901 to Treat Diabetic Macular Edemahttps://modernod.com/news/eyepoint-begins-phase-2-verona-clinical-trial-of-eyp-1901-to-treat-diabetic-macular-edema/2482049/EyePoint Pharmaceuticals, a company focused on therapeutics for retinal diseases, announced that the first patient has been dosed in the VERONA clinical trial of the company’s EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vor
- EssilorLuxottica Showcases Nuance Audio Smart Eyewear With Hearing-Aid Solutionhttps://modernod.com/news/essilorluxottica-showcases-nuance-audio-smart-eyewear-with-hearing-aid-solution/2482051/EssilorLuxottica announced it will showcase its consumer technology at CES 2024, the Consumer Electronics Show held by the Consumer Technology Association on January 9-12 in Las Vegas, Nevada. The company is a France-based designer, manufacturer, and global distributor of eyecare and eyewear prod
- Gentex Acquires eSighthttps://modernod.com/news/gentex-acquires-esight/2482048/Gentex announced the asset acquisition of eSight, a provider of vision enhancement technologies, to develop and manufacture next-generation mobile electronic eyewear that is designed to help people living with visual impairments. The company will feature eSight’s technology at CES 2024, the
- Eylea 8 mg Approved in EUhttps://modernod.com/news/eylea-8-mg-approved-in-eu/2482046/The European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME).
- Bausch + Lomb and Glaucoma Research Foundation Launch 'Faces of Glaucoma' Campaignhttps://modernod.com/news/bausch-lomb-and-glaucoma-research-foundation-launch-faces-of-glaucoma-campaign/2482039/Bausch + Lomb and the Glaucoma Research Foundation (GRF) have launched “Faces of Glaucoma,” a campaign that will highlight diverse patient stories and raise awareness of the second leading cause of blindness worldwide. The campaign will run through January, which is Glaucoma
- Sight Sciences Announces Withdrawal of Final LCDs on MIGS from Five Medicare Administrative Contractorshttps://modernod.com/news/sight-sciences-announces-withdrawal-of-final-lcds-on-micro-invasive-glaucoma-surgery-from-five-medicare-administrative-contractors/2482031/In a major decision that could a have wide-reaching effect on the future of reimbursement and access to care for glaucoma patients, five Medicare Administrative Contractors (MACs) decided to withdraw their final local coverage determinations (LCDs) for certain Micro-Invasive Glaucoma Su
- Aetna Rolls Back Prior Authorization for Cataract Surgeries for Medicare Advantage Beneficiaries in Georgiahttps://modernod.com/news/aetna-rolls-back-prior-authorization-for-cataract-surgeries-for-medicare-advantage-beneficiaries-in-georgia-1/2482030/After 2 years of advocacy from the ophthalmology community, Aetna confirmed in a letter to the American Academy of Ophthalmology that it will no longer require preapproval for cataract surgeries for Medicare Advantage beneficiaries in Georgia, starting Jan.1. Last year, the insurer rolled back th